Is it safe to restart Lexapro (escitalopram) after symptoms of depression recur?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Restarting Lexapro After Symptom Recurrence

Yes, it is safe and appropriate to restart Lexapro (escitalopram) after depressive symptoms recur, and you should resume the previously effective dose that achieved remission. 1

Immediate Restart Strategy

If intolerable symptoms occur following discontinuation or if depression recurs, resume the previously prescribed dose that was effective. 1 The FDA label explicitly supports this approach, indicating that returning to the prior therapeutic dose is the recommended strategy when symptoms return after stopping treatment.

  • Restart at the same dose that previously achieved remission rather than starting at a lower dose 1
  • This approach minimizes the time to symptom control and avoids the delay associated with dose titration 2

Duration of Continued Treatment After Restart

Once restarted, continue escitalopram for a minimum of 9-12 months after achieving recovery to prevent another relapse. 3, 4

  • For patients with recurrent depression (2 or more episodes), treatment duration should extend to years or potentially lifelong, as recurrence risk escalates dramatically: 50% after first episode, 70% after two episodes, and 90% after three episodes 5
  • The greatest relapse risk occurs in the first 8-12 weeks after any future discontinuation 5

Monitoring Requirements After Restart

Assess the patient in person within 1 week of restarting treatment, then continue monthly monitoring for 6-12 months after achieving full symptom resolution. 5

At each visit, evaluate:

  • Ongoing depressive symptoms and functional status 5
  • Suicide risk assessment 5
  • Adverse effects and tolerability 5
  • Treatment adherence 5
  • Environmental stressors 5

Safety Profile Upon Restart

Escitalopram demonstrates a predictable and favorable safety profile with generally mild to moderate, transient adverse events 2, 6:

  • No new types of adverse events emerge with long-term treatment, and incidence actually declines over time 6
  • The drug has minimal clinically relevant drug interactions due to multiple metabolic pathways 7
  • It is generally better tolerated compared to other antidepressants with a relatively fast onset of action 7

Critical Pitfall to Avoid

Do not discontinue treatment prematurely when symptoms improve after restarting. 5 This dramatically increases relapse risk and perpetuates a cycle of recurrence. Many patients who stop after only one prescription fail to complete an adequate treatment course—only 29.3% of those who restart after early discontinuation continue for 6 months or more 8.

Special Populations

  • For elderly patients or those with hepatic impairment, the recommended dose is 10 mg/day 1
  • Use with caution in severe renal impairment, though no adjustment is needed for mild to moderate renal impairment 1
  • Screen for personal or family history of bipolar disorder prior to restarting, as antidepressants can precipitate mania 1

Drug Interaction Precautions When Restarting

Allow at least 14 days between discontinuation of any MAOI and restarting escitalopram, and vice versa. 1 Do not start escitalopram in patients receiving linezolid or intravenous methylene blue due to serotonin syndrome risk 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Medication Management for Depression in Patients with Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Duration of Escitalopram Treatment After Symptom Improvement

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Escitalopram in the long-term treatment of major depressive disorder.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.